Simultaneous Imaging of Ga-DOTA-TATE and Lu-DOTA-TATE in Murine Models of Neuroblastoma
- PMID: 37635919
- PMCID: PMC10448760
- DOI: 10.1109/trpms.2022.3201757
Simultaneous Imaging of Ga-DOTA-TATE and Lu-DOTA-TATE in Murine Models of Neuroblastoma
Abstract
68Ga-DOTA-TATE and 177Lu-DOTA-TATE are radiolabeled somatostatin analogs used to detect or treat neuroendocrine tumors. They are administered separately for either diagnostic or therapeutic purposes but little experimental data for their biokinetics are measured simultaneously in the same biological model. By co-administering 68Ga-DOTA-TATE and 177Lu-DOTA-TATE in three laboratory mice bearing two IMR32 tumor xenografts expressing different levels of somatostatin receptors (SSTRs) on their shoulders and imaging both 68Ga and 177Lu simultaneously, we investigated the relationship between the uptake of 68Ga-DOTA-TATE and 177Lu-DOTA-TATE in organs and tumors. In addition, using the percent of injected activity (%IA) values of 68Ga-DOTA-TATE at 0 hr and 4 hr, we investigated the correlation between 68Ga-DOTA-TATE %IA and the time-integrated activity coefficients (TIACs) of 177Lu-DOTA-TATE to estimate the organ-based and tumor-based doses of 177Lu-DOTA-TATE. The results showed that the extrapolated clearance time of 68Ga-DOTA-TATE linearly correlated with the TIACs of 177Lu-DOTA-TATE in the IMR32-SSTR2 tumor, kidneys, brain, heart, liver, stomach and remainder body. The extrapolated %IA value at 0 hr of 68Ga-DOTA-TATE linearly correlated with the TIACs of 177Lu-DOTA-TATE in the IMR32 tumor and lungs. In our murine study, both kidneys and lungs were organs that showed high absorbed doses of 177Lu-DOTA-TATE.
Keywords: 177Lu-DOTA-TATE; 68Ga-DOTA-TATE; IMR32; SSTR; neuroblastoma; neuroendocrine tumor; radiation dosimetry; somatostatin receptor.
Figures






References
-
- Sackstein PE, O’Neil DS, Neugut AI, Chabot J, and Fojo T, “Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years,” in Seminars in oncology, vol. 45, no. 4. Elsevier, 2018, pp. 249–258. - PubMed
-
- Kennedy J, Chicheportiche A, and Keidar Z, “Quantitative SPECT/CT for dosimetry of peptide receptor radionuclide therapy,” in Seminars in nuclear medicine, vol. 52, no. 2, pp. 229–242, 2022. - PubMed
-
- Seo Y, Huh Y, Huang S.-y., Hernandez-Pampaloni JM, Hawkins RA, Gustafson WC, Vo KT, and Matthay KK, “Simplified and practical pretherapy tumor dosimetry—a feasibility study for 131I-MIBG therapy of neuroblastoma using 124I-MIBG PET/CT,” Medical physics, vol. 46, no. 5, pp. 2477–2486, 2019. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous